# Ivonescimab Monotherapy or in Combination With Chemotherapy as Neoadjuvant/Adjuvant Therapy for Resectable Non-small Cell Lung Cancer

> **NCT07241819** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 66 (estimated)

## Conditions studied

- II-IIIB (T3N2) Resectable Non-small Cell Lung Cancer
- Perioperative

## Interventions

- **COMBINATION_PRODUCT:** Ivonescimab/surgery
- **COMBINATION_PRODUCT:** Ivonescimab/chemotherapy/surgery
- **COMBINATION_PRODUCT:** Ivonescimab/chemotherapy/surgery
- **COMBINATION_PRODUCT:** Ivonescimab/chemotherapy/surgery

## Key facts

- **NCT ID:** NCT07241819
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11-30
- **Primary completion:** 2027-11-30
- **Final completion:** 2028-11-30
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07241819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07241819, "Ivonescimab Monotherapy or in Combination With Chemotherapy as Neoadjuvant/Adjuvant Therapy for Resectable Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07241819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*